For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome

Hello. We're improving abcam.com and we'd welcome your feedback.

Hello. We're improving abcam.com and we'd welcome your feedback.

Infomation icon

We haven't added this to the BETA yet

New BETA website

New BETA website

Hello. We're improving abcam.com and we'd welcome your feedback.

Take a look at our BETA site and see what we’ve done so far.

Switch on our new BETA site

Now available

Search and browse selected products

  • A selection of primary antibodies

Purchase these through your usual distributor

In the coming months

  • Additional product types
  • Supporting content
  • Sign in to your account
  • Purchase online
United States
Your country/region is currently set to:

If incorrect, please enter your country/region into the box below, to view site information related to your country/region.

Call (888) 77-ABCAM (22226) or contact us
Need help? Contact us

  • My account
  • Sign out
Sign in or Register with us

Welcome

Sign in or

Don't have an account?

Register with us
My basket
Quick order
Abcam homepage

  • Research Products
    By product type
    Primary antibodies
    Secondary antibodies
    ELISA and Matched Antibody Pair Kits
    Cell and tissue imaging tools
    Cellular and biochemical assays
    Proteins and Peptides
    By product type
    Proteomics tools
    Agonists, activators, antagonists and inhibitors
    Cell lines and Lysates
    Multiplex miRNA assays
    Multiplex Assays
    By research area
    Cancer
    Cardiovascular
    Cell Biology
    Epigenetics
    Metabolism
    Developmental Biology
    By research area
    Immunology
    Microbiology
    Neuroscience
    Signal Transduction
    Stem Cells
  • Customized Products & Partnerships
    Customized Products & Partnerships

    Customized products and commercial partnerships to accelerate your diagnostic and therapeutic programs.

    Customized products

    Partner with us

  • Support
    Support hub

    Access advice and support for any research roadblock

    View support hub

    Protocols

    Your experiments laid out step by step

    View protocols

  • Events
    • Conference calendar
    • Cancer
    • Cardiovascular
    • Epigenetics & Nuclear signaling
    • Immunology
    • Neuroscience
    • Stem cells
    • Tradeshows
    • Scientific webinars
    Keep up to date with the latest events

    Full event breakdown with abstracts, speakers, registration and more

    View global event calendar

  • Pathways
    Cell signalling pathways

    View all pathways

    View all interactive pathways

Pharmacology term guide

Related

  • Biochemicals FAQ
    • Receptors & transporter agonists & antagonists
      • Signaling & enzyme inhibitors & activators
        • Ion channel modulators

          This guide is a quick reference guide to the important concepts and terms used in pharmacology. 

          ​​Reviewed December 14 2020​

          The information is not intended to be an exhaustive list, but to provide assistance to those researchers who are new to this field of research.

          Definitions of commonly used pharmacological terms:

          Agonist:
          ​
          A drug capable of binding and activating a receptor, leading to a pharmacological response that may mimic that of a naturally occurring substance. Can be classified as full, partial or inverse.

          • Full agonist - Is capable of eliciting a maximal response as it displays full efficacy at that receptor.

          • Partial agonist - Binds to and activates a receptor but is only able to elicit partial efficacy at that receptor. A maximal effect cannot be produced, even when the concentration is increased. When full and partial agonists are present the partial agonist may act as a competitive antagonist.
          • Inverse agonist - Produces an effect that is pharmacologically opposite to an agonist, yet acts at the same receptor. The receptor must elicit intrinsic or basal activity in the absence of a ligand and the addition of an inverse agonist will decrease the activity below the basal level. A receptor that possesses basal activity is the GABAA receptor; agonists have a sedative effect whilst inverse agonists have an anxiogenic effect.

           
          Antagonist:
          Does not produce a biological response on binding to a receptor but instead blocks or reduces the effect of an agonist. It may be competitive or non-competitive.

          • Competitive antagonist - competitive antagonists bind selectively to the active site of the receptor without causing activation, preventing the agonist from binding and causing its effect. The antagonism may be reversible; the effect can be overcome by increasing the concentration of the agonist, which will lead to a shift in the equilibrium. 
          • Non-competitive antagonist - non-competitive antagonists may affect the reaction by irreversibly binding to the active site of the receptor or to an allosteric site, therefore not competing with the agonist. The magnitude of the maximal response is reduced, regardless of the amount of agonist present.

          Physiological agonists and antagonists
          Physiological agonists are drugs that mediate the same physiological parameters via alternative receptors or mechanisms. Physiological antagonists reduce or block the physiological effect of an agonist by causing an opposite physiological response without binding to the same receptor. Physiological antagonism is a non-competive form of antagonism.  

          Allosteric modulator:

          ​A drug that binds to a receptor at a site distinct from the active site. A conformational change is induced in the receptor, altering the affinity of the receptor for the endogenous ligand.

          • Positive allosteric modulators - Increase the affinity of the receptor for the endogenous ligand.
          • Negative allosteric modulators - Decrease the affinity of the receptor for the endogenous ligand.

           
          Bmax:
          Maximum amount of drug which can bind specifically to receptors in a membrane preparation. If one drug molecule binds to each receptor it acts as an indication of the concentration of receptors in the tissue.
           
          Cheng-Prusoff equation:
          Used to determine the Ki value from an IC50 value.

          Concentration response curve:
          An example concentration response curve in a typical in vitro preparation. Curve A represents a full agonist (EC50 = 3 x 10-8 M) whilst curve B is a partial agonist acting on the same receptor.

          Desensitization - A loss of responsiveness which may be due to the continued presence of an agonist at a receptor or repeated presentation of the agonist.
           
          EC50 - The molar concentration of an agonist that produces a 50% response of the maximum possible response for that agonist. Figures may also be stated as other percentages of the maximum response EC20 and EC80 representing a 20% and 80% response respectively.
           
          ED50 - Dose of drug that produces 50% of its maximum response or effect. Can be a term used in vitro or in vivo (although it is more common in vivo).
           
          Efficacy - Used to describe agonist responses in relation to receptor occupation. High efficacy agonists can produce a maximal response whilst occupying a relatively low proportion of receptors. Low efficacy agonists are unable to cause receptor activation to the same degree and a maximal response may not be achieved even at full occupation of the entire receptor population. Low efficacy agonists are often termed partial agonist.
           
          Ex vivo - Experimentation using tissue in an artificial environment outside the living organism. An example may include short-term (up to 24 hour) culture of tissue, following its removal from the organism.
           
          Half-life (t½) - An important pharmacokinetic measurement. The metabolic half-life of a drug in vivo is the time taken for its concentration in plasma to decline to half its original level. t½ refers to the duration of action of a drug and depends upon how quickly the drug is eliminated from the plasma.
          Clearance and distribution of a drug from the plasma are important parameters for half-life determination.

          IC50 - Molar concentration of an agonist or antagonist that causes 50% of the maximum possible inhibition. Figures may also be stated as other percentages of the inhibition.

          In vitro - Studies carried out using components of an organism that have been isolated from their usual biological surroundings. The analysis is usually carried out in test-tubes or culture dishes.
           
          In vivo - Experimentation using the whole living organism. Normal physiology will be involved in any response.

          KA - Equilibrium dissociation constant for an agonist; the concentration at which 50% of receptors would be occupied at equilibrium.
           
          KB - The equilibrium dissociation constant for a competitive antagonist; the concentration at which 50% of the receptors would be occupied at equilibrium.
           
          Kd - The dissociation constant. Concentration of a drug which at equilibrium occupies 50% of receptors.
           
          Ki - Inhibition constant for a drug where 50% of receptors will be occupied. Provides an absolute value and does not differ between experiments. Calculated from the IC50 value using the Cheng-Prusoff equation.

          Non-specific binding:
          Proportion of radioligand that is not displaced by other competitive ligands that are specific for a particular receptor. It can be due to:

          • Binding to other receptors or proteins
          • Partitioning into lipids

          pA2 - Logarithmic measure of antagonist potency. It is the negative log of the molar concentration of an antagonist that would produce a 2-fold shift in the concentration response curve for an agonist.
           
          pD2 - Negative logarithm of the EC50 or IC50 value.
           
          pEC50 - Negative logarithm of the EC50 value.
           
          pIC50 - Negative logarithm of the IC50 value.
           
          pKA - Negative logarithmic measure of the potency of an antagonist.
           
          pKB - Negative logarithm of KB value. For a competitive antagonist the pKB theoretically equals the pA2 value.
           
          pKd - Negative logarithm of the Kd value.
           
          pKi - Negative logarithm of the Ki value.
           
          Potency:
          Measure of the effective concentration of a drug. It is a vague term and it is advisable to further categorise the measurement:

          • Agonists – EC50, IC50 or pD2
          • Antagonists – pA2, KB or pKB

          Occupancy - The proportion of receptors to which a drug is bound.

          [D] = Drug concentration
          K = Dissociation constant

          Discover more
          Get resources and offers direct to your inbox Sign up
          A-Z by research area
          • Cancer
          • Cardiovascular
          • Cell biology
          • Developmental biology
          • Epigenetics & Nuclear signaling
          • Immunology
          • Metabolism
          • Microbiology
          • Neuroscience
          • Signal transduction
          • Stem cells
          A-Z by product type
          • Primary antibodies
          • Secondary antibodies
          • Biochemicals
          • Isotype controls
          • Flow cytometry multi-color selector
          • Kits
          • Loading controls
          • Lysates
          • Peptides
          • Proteins
          • Slides
          • Tags and cell markers
          • Tools & Reagents
          Help & support
          • Support
          • Make an Inquiry
          • Protocols & troubleshooting
          • Placing an order
          • RabMAb products
          • Biochemical product FAQs
          • Training
          • Browse by Target
          Company
          • Corporate site
          • Investor relations
          • Company news
          • Careers
          • About us
          • Blog
          Events
          • Tradeshows
          • Conferences
          International websites
          • abcam.cn
          • abcam.co.jp

          Join with us

          • LinkedIn
          • facebook
          • Twitter
          • YouTube
          • Terms of sale
          • Website terms of use
          • Cookie policy
          • Privacy policy
          • Legal
          • Modern slavery statement
          © 1998-2022 Abcam plc. All rights reserved.